FindTrial
Sign In

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in end-stage renal disease patients undergoing hemodialysis: a retrospective study based on medical records

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in end-stage renal disease patients undergoing hemodialysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034389
Enrollment
Unknown
Registered
2020-07-04
Start date
2020-07-17
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis C

Interventions

treatment group:GZR/EBR

Sponsors

The Second Hospital of Nanjing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: This retrospective study enrolled the patients underwent hemodialysis who had AHC because of the nosocomial HCV infection in a medical negligence, and who had CHC (positive HCV RNA for more than 6 months).

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
HCV RNA;—

Countries

china

Contacts

Public ContactYe wei

The Second Hospital of Nanjing

yeweiseu@163.com+86 13951729085

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026